focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 111.80
Bid: 112.00
Ask: 112.40
Change: -0.40 (-0.36%)
Spread: 0.40 (0.357%)
Open: 112.80
High: 112.80
Low: 111.80
Prev. Close: 112.20
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2021 09:12

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

Read more
22 Dec 2021 08:50

Novartis buys UK gene therapy firm Gyroscope for up to USD1.5 billion

Novartis buys UK gene therapy firm Gyroscope for up to USD1.5 billion

Read more
22 Dec 2021 07:03

Syncona sells Gyroscope to Novartis for up to $1.5bn

(Sharecast News) - Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.

Read more
14 Dec 2021 12:24

Syncona portfolio firm Freeline cuts workforce and narrows focus

Syncona portfolio firm Freeline cuts workforce and narrows focus

Read more
29 Nov 2021 10:04

Syncona invests GBP19 million in Quell Therapeutics via funding round

Syncona invests GBP19 million in Quell Therapeutics via funding round

Read more
22 Nov 2021 15:57

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

Read more
11 Nov 2021 14:30

IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit

IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit

Read more
11 Nov 2021 09:42

Syncona net asset value slips in first half

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down from £1.3bn or 193.8p per share at the end of March.

Read more
10 Nov 2021 10:51

Syncona's Freeline loss widens but progresses on Fabry's disease drug

Syncona's Freeline loss widens but progresses on Fabry's disease drug

Read more
10 Nov 2021 08:13

Syncona's Freeline makes progress in dose-finding trials

(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' dose-finding clinical trial of 'FLT190' for the treatment of Fabry disease on Wednesday, with the second patient dosed generating "encouraging" data.

Read more
9 Nov 2021 19:18

TRADING UPDATES: Sealand's China progress; Altus finds gold

TRADING UPDATES: Sealand's China progress; Altus finds gold

Read more
8 Nov 2021 09:37

Syncona's Autolus gets USD250 million investment from Blackstone

Syncona's Autolus gets USD250 million investment from Blackstone

Read more
4 Nov 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
3 Nov 2021 14:38

TRADING UPDATES: BATM signs new deal; Synectics wins two projects

TRADING UPDATES: BATM signs new deal; Synectics wins two projects

Read more
17 Aug 2021 11:33

Syncona focuses on portfolio as net asset value drops in first quarter

Syncona focuses on portfolio as net asset value drops in first quarter

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.